Vyome Holdings HIND
NASDAQ HIND
$2.06 -0.03 (-1.44%)
As of: Sep 9, 2026 · 3:59 PM EDT

Vyome Holdings (HIND) Research & Development (2015 - 2026)

Vyome Holdings (HIND) posted Research & Development of $506723.0 for Q2 2026, down 23.96% on a QoQ basis from $666405.0 in Q1 2026, and up 532.92% year-over-year from $80061.0 in Q2 2025.

Analysis

Vyome Holdings (HIND) Research & Development (2015 - 2026) Analysis & Trends

Vyome Holdings has reported Research & Development for 12 years, with the latest figure at $506723.0 in Q2 2026.

  • On a quarterly basis, Research & Development rose 532.92% year-over-year to $506723.0 in Q2 2026; TTM through Jun 2026 was $1.6 million, a 422.22% increase from a year earlier, with the FY2025 full-year figure at $588258.0, up 106.12% from the prior year.
  • Research & Development was $506723.0 for Q2 2026 at Vyome Holdings, down from $666405.0 in the prior quarter.
  • The five-year high for Research & Development was $6.0 million in Q4 2023, with the low at $39677.0 in Q3 2025.
  • Average Research & Development over 5 years is $759429.3, with a median of $524361.5 recorded in 2023.
  • The sharpest annual moves came in 2023 and 2024: Research & Development soared 1192.64% in 2023, then sank 98.87% in 2024.
  • Over 5 years, Research & Development stood at $462000.0 in 2022, then jumped by 1192.64% to $6.0 million in 2023, then tumbled by 98.87% to $67527.0 in 2024, then soared by 460.15% to $378252.0 in 2025, then surged by 33.96% to $506723.0 in 2026.
  • The last three Research & Development figures came in at $506723.0 (Q2 2026), $666405.0 (Q1 2026), and $378252.0 (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 1.87 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 1.76 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 993.80 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 1.63 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -486.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 651.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 413.13 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 529.60 Mn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 202.02 Mn
10 Vyome Holdings 14.46 Mn 6.57 Mn 11,658.00 506,723.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 506,723.00
Mar 31, 2026 666,405.00
Dec 31, 2025 378,252.00
Sep 30, 2025 39,677.00
Jun 30, 2025 80,061.00
Mar 31, 2025 90,268.00
Dec 31, 2024 67,527.00
Sep 30, 2024 66,815.00
Jun 30, 2024 670,000.00
Mar 31, 2024 1.02 Mn
Dec 31, 2023 5.97 Mn
Sep 30, 2023 542,000.00
Jun 30, 2023 581,000.00
Mar 31, 2023 453,000.00
Dec 31, 2022 462,000.00
Sep 30, 2022 583,000.00
Jun 30, 2022 747,000.00
Mar 31, 2022 745,000.00
Dec 31, 2021 270,000.00
Sep 30, 2021 1.43 Mn